Baseline and procedure characteristics of patients with futile recanalisation and effective recanalisation
| Baseline and procedure variables | Futile recanalisation (n=155) | Effective recanalisation (n=160) | P value |
| Age, years, median (IQR) | 64 (55–72) | 64 (54–72) | 0.499 |
| Male sex, n (%) | 120 (77.4) | 130 (81.3) | 0.401 |
| Admission mode, n (%) | 0.490 | ||
| Mothership | 90 (58.1) | 99 (61.9) | |
| Drip and ship | 65 (41.9) | 61 (38.1) | |
| Hypertension, n (%) | 105 (67.7) | 113 (70.6) | 0.580 |
| DM, n (%) | 37 (23.9) | 33 (20.6) | 0.488 |
| Hyperlipidaemia, n (%) | 18 (11.6) | 26 (16.3) | 0.235 |
| Coronary heart disease, n (%) | 26 (16.8) | 25 (15.6) | 0.782 |
| Atrial fibrillation, n (%) | 21 (13.6) | 23 (14.4) | 0.832 |
| Prior stroke, n (%) | 44 (28.4) | 44 (27.5) | 0.861 |
| Smoking history, n (%) | 0.233 | ||
| Never smoking | 83 (53.6) | 76 (47.5) | |
| Previous smoking | 11 (7.1) | 20 (12.5) | |
| Current smoking | 61 (39.4) | 64 (40.0) | |
| SBP, mmHg | 150 (135–167) | 153 (136–164) | 0.644 |
| Admission NIHSS* | 29(19-35) | 15(8-26) | <0.001 |
| Admission PC-ASPECTS† | 9 (6–10) | 9 (7–10) | 0.149 |
| Serum glucose, mmol/L, median (IQR) | 7.9 (6.6–10.5) | 7.5 (6.4–10.1) | 0.355 |
| Blood WCC, ×109 /L, median (IQR) | 10.3 (8.2–13.4) | 10.0 (8.0–12.5) | 0.113 |
| NLR, median (IQR) | 7.8 (3.8–11.7) | 5.8 (3.1–9.3) | 0.018 |
| PLR, median (IQR) | 179.4 (125.8–230.7) | 149.0 (103.1–215.7) | 0.026 |
| PLT, ×109/L, median (IQR) | 221.5 (184.0–251.0) | 216.0 (182.0–262.0) | 0.967 |
| Prior use of antiplatelet agents, n (%) | 24 (15.5) | 33 (20.6) | 0.236 |
| Prior use of anticoagulants, n (%) | 3 (1.9) | 5 (3.1) | 0.723 |
| Prior IVT, n (%) | 38(24.5) | 45(28.1) | 0.467 |
| Tandem occlusion, n (%) | 33 (21.3) | 23 (14.4) | 0.109 |
| Underlying ICAD, n (%) | 0.760 | ||
| Yes | 76 (49.0) | 73 (45.6) | |
| No | 63 (40.7) | 67 (41.9) | |
| Undetermined | 16 (10.3) | 20 (12.5) | |
| TOAST subtypes, n (%) | 0.106 | ||
| Large artery atherosclerosis | 96 (61.9) | 108 (67.5) | |
| Cardioembolism | 29 (18.7) | 30 (18.8) | |
| Other or unknown | 22 (14.2) | 21 (13.1) | |
| Undetermined | 8 (5.2) | 1 (0.6) | |
| General anaesthesia, n (%) | 100 (64.5) | 82 (51.3) | 0.017 |
| Heparin, n (%) | 89 (57.4) | 75 (46.9) | 0.061 |
| GP IIb/IIIa receptor inhibitor, n (%) | 109 (70.3) | 99 (61.9) | 0.114 |
| Stent retriever as first line, n (%) | 107 (69.0) | 105 (65.6) | 0.519 |
| Direct aspiration as first line, n (%) | 10 (6.5) | 6 (3.8) | 0.275 |
| Direct aspiration+stent retriever as first-line | 13 (8.4) | 18 (11.3) | 0.394 |
| IAT, n (%) | 13 (8.4) | 12 (7.5) | 0.771 |
| Rescue balloon/ stenting angioplasty, n (%) | 51 (32.9) | 48 (30.0) | 0.579 |
| Complete recanalisation, n (%) | 104 (67.1) | 111 (69.4) | 0.664 |
| No. of MT passes, median (IQR) | 1 (1–2) | 1 (1–2) | 0.151 |
| OTP, min, median(IQR) | 341 (230–439) | 275 (185–399) | 0.007 |
| Procedure duration, min, median(IQR) | 96(60-145) | 84(53-120) | 0.058 |
Bold values indicate statistical significance.
*Two missing data.
†Six missing data.
‡
DM, diabetes mellitus; IAT, intra-arterial thrombolysis; ICAD, intracranial atherosclerotic disease; IVT, intravenous thrombolysis; MT, mechanical thrombectomy; NIHSS, National Institute of Health Stroke Scale; NLR, neutrophil to lymphocyte ratio; OTP, Onset-to-puncture time; PC-ASPECTS, Posterior Circulation Alberta Stroke Programme Early CT Score; PLR, platelet to lymphocyte ratio; PLT, platelet; SBP, systolic blood pressure; TOAST, Trial of ORG 10172 in Acute Stroke Treatment; WCC, white cell count.